Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V

Related Experiment Video

Updated: Mar 17, 2026

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

4.3K

Maximilien Murone1, Anne Vaslin Chessex2, Antoine Attinger2

  • 1Debiopharm International S.A., Lausanne, Switzerland. mmurone@adipogen.com.

Molecular Cancer Therapeutics
|July 22, 2016
PubMed

Insights

Debio 0617B effectively inhibits STAT3 and STAT5 signaling in solid tumors, demonstrating potent anti-cancer activity and reducing metastasis. It shows synergistic effects when combined with EGFR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • STAT3 and STAT5 activation are linked to cancer progression, immune evasion, and treatment resistance.
  • Targeting these signaling pathways presents a therapeutic strategy for various solid tumors.

Purpose of the Study:

  • To evaluate the efficacy of Debio 0617B, a novel kinase inhibitor targeting phospho-STAT3 (pSTAT3) and phospho-STAT5 (pSTAT5).
  • To assess Debio 0617B's activity as a monotherapy and in combination with erlotinib in preclinical cancer models.

Main Methods:

  • Debio 0617B's inhibition of pSTAT3 and pSTAT5 was assessed in cancer cell lines.
  • Antiproliferative effects were evaluated using clonogenic assays and patient-derived tumor xenografts.
  • In vivo efficacy was studied in mouse xenograft models, including combination therapy and metastasis assessment.

Main Results:

  • Debio 0617B demonstrated dose-dependent inhibition of pSTAT3 and potent antiproliferative activity.
  • The drug showed significant tumor growth inhibition in vivo across multiple xenograft models.
  • Combination with erlotinib enhanced efficacy, and Debio 0617B reduced tumor metastasis in an orthotopic model.

Conclusions:

  • Debio 0617B exhibits potent activity against a wide range of STAT3-driven solid tumors.
  • The drug displays synergistic effects with EGFR inhibition and therapeutic efficacy in reducing tumor burden and metastasis.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.7K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K